Axisresearch
List of Categories
- Aerospace & Defense
- Agriculture
- Animal Nutrition & Wellness
- Automation
- Automotive
- Chemical & Materials
- Consumer Goods and Services
- Electronics
- Energy & Mining
- Financial Services & Investment Intelligence
- Food & Beverage
- Healthcare
- Heavy Industry
- Home & Property Improvement
- Information & Communications Technology
- Investment Opportunities
- Manufacturing
- NEO
- Others
- Packaging
- Retail
- Technology & Media
- Transportation & Logistics
Sorted by Name
Publishers
Countries
Whole Exome Sequencing Market- Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 110 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 110 pages
- Published: 07-06-2019
Market Overview
The key factors propelling the global whole exome sequencing market are the increasing applications in clinical diagnosis, high demand for the diagnosis of rare diseases, increasing R&D in the field of genomics and next-generation sequencing, and increasing demand for personalized medicine.
The increase in acceptance of next-generation sequencing methods for prediction, treatment, and monitoring of diverse chronic diseases, such as cancer, is driving the overall market.
The low cost and high speed associated with whole exome sequencing technology, technological advancements in whole exome sequencing techniques, and global alliances among leading research institutes, are some of the major driving forces for the global whole exome sequencing market.
Scope of the Report
Exome sequencing is a technique for sequencing all of the exome and protein-coding genes in a genome. This technique includes selection of the subset of DNA that encodes proteins or exons, followed by sequencing of the exonic DNA using high-throughput DNA sequencing methods. Currently, it is being widely used for the identification and the determination of genetic variants causing various diseases, such as Miller syndrome and Alzheimer’s disease. It also provides a cost-effective screening approach for the diagnosis of genetic disorders, and presents itself as a less resource-intensive alternative to whole genome sequencing in several applications, including drug discovery and development processes.
Key Market Trends
Personalized Medicine Segment by Application is Expected to Grow the Fastest During the Forecast Period
Personalized medicine aims to provide tailor-made therapies to individual patients, depending on the molecular basis of disease, and it has become popular over recent years. Rising demand for personalized medicine has created tremendous opportunities in the field of genetic medicine, and in order to exploit these opportunities, novel diagnostic and therapeutic technologies must be developed, which in turn, has resulted in the rapid expansion of the global whole exome sequencing market.
North America holds the Largest Market and is Expected to Follow the Same Trend Over the Forecast Period
North America has the largest regional market, in terms of revenue. The increasing prevalence of genetic and chronic disorders, such as cancer, ageing population, increasing demand for targeted and personalized medicine, and favorable government initiatives, are the primary factors behind the growth of the whole exome sequencing market.
Asia-Pacific is expected to be the fastest-growing market for whole exome sequencing. Regular government funding and large numbers of conferences related to the whole exome sequencing technique are the major driving forces for the Asia-Pacific whole exome sequencing market.
Competitive Landscape
There are key players that have adopted strategies, such as collaborations, partnerships, agreements, and new product launches to gain a competitive advantage in the market. In addition, the high investments made by companies, both new and old, are on R&D facilities in this technology, which are also impacting the growth of the market.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1. Introduction
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. Research Methodology
3. Executive Summary
4. Market Dynamics
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Applications in the Clinical Diagnosis and High Demand for the Diagnosis of Rare Diseases
4.2.2 Increasing R&D in the Field of Genomics and Next-generation Sequencing
4.2.3 Increasing Demand for Personalized Medicine
4.3 Market Restraints
4.3.1 High Complexity of Technique and Lack of Skilled Personnel
4.3.2 Legal and Ethical Issues Associated with Whole Exome Sequencing
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. Market Segmentation
5.1 By Product
5.1.1 Systems
5.1.2 Kits
5.1.2.1 Library Preparation Kits
5.1.2.2 Target Enrichment Kits
5.1.3 Services
5.1.3.1 Sequencing Services
5.1.3.2 Data Analysis (Bioinformatics) Services
5.1.3.3 Other Services
5.2 By Technology
5.2.1 Second-generation Sequencing
5.2.1.1 Sequencing, by Synthesis (SBS)
5.2.1.2 Sequencing, by Hybridization and Ligation (SBL)
5.2.2 Third-generation Sequencing
5.3 By Application
5.3.1 Diagnostics
5.3.2 Drug Discovery and Development
5.3.3 Personalized Medicine
5.3.4 Other Applications (Agriculture, Animal Research, etc.)
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East & Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East & Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6. Competitive Landscape
6.1 Company Profiles
6.1.1 Agilent Technologies Inc.
6.1.2 Ambry Genetics Corp.
6.1.3 Beijing Genomics Institute
6.1.4 Bio-Rad Laboratories Inc.
6.1.5 Eurofins Scientific Group
6.1.6 F. Hoffmann-La Roche AG
6.1.7 GENEWIZ Inc.
6.1.8 Illumina Inc.
6.1.9 Macrogen Inc.
6.1.10 Pacific Biosciences of California Inc.
7. Market Opportunities and Future Trends
Market Segmentation
- By Product
Systems
Kits
Library Preparation Kits
Target Enrichment Kits
Services
Sequencing Services
Data Analysis (Bioinformatics) Services
Other Services
By Technology
Second-generation Sequencing
Sequencing, by Synthesis (SBS)
Sequencing, by Hybridization and Ligation (SBL)
Third-generation Sequencing
By Application
Diagnostics
Drug Discovery and Development
Personalized Medicine
Other Applications (Agriculture, Animal Research, etc.)
Geography
North America
United States
Canada
Mexico - Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Apheresis Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 118 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 118 pages
- Published: 07-06-2019
Market Overview
The propelling factors for the growth of the apheresis market include the increasing number of diseases, a rise in the demand for blood components and associated safety, technological advancement in the development of new apheresis techniques, and rise in the reimbursement policies and funding for apheresis procedures. Due to the aforementioned factors, the apheresis market is expected to experience a boost during the forecast period.
With the increasing number of surgeries and surgical techniques, advanced treatments have led to global demand for blood and the blood components. The need for blood components is significantly growing and contributing to healthcare spending. Apheresis has also recently witnessed a high demand due to an increased number of patients suffering from various ailments related to blood, kidney, metabolic diseases, and neurological disorders. Therefore, apheresis technology is used to reduce the number of white cells, until other medications can control them. With the steady increase in the number of patients suffering from these diseases, ailments, and the technical ease of using these devices in the treatment of these diseases, requiring a minimal hospital stay, the global apheresis market is poised to experience growth during the forecast period.
The use of apheresis in clinically ill patients is increasing day by day, and it has been widely used as the primary therapy or as an adjunct to other treatments for various diseases, such as thrombotic thrombocytopenic purpura, hemolytic uremic syndrome, drug toxicities, autoimmune disease, sepsis, and fulminant hepatic failure.
Therefore with the steady increase in the number of patients suffering from these diseases, ailments, and the technical ease of using these devices in the treatment of these diseases, thus requiring a minimal hospital stay, the global apheresis market is poised to experience growth during the forecast period.
The Scope of the Report
As per the scope of the report, apheresis is a medical technique where the blood of an individual, be a donor or a patient, is passed through an apparatus that segregates out a particular constituent and returns the rest to the blood circulation. It involves blood purification and blood component separation by using centrifugation or membrane filtration technology. This procedure is performed for blood donation component or for the treatment of disease.
Key Market Trends
Hematological Disorders is the Segment under Application that is Expected to Grow Fastest during the Forecast Period
Hematological disorders are found common in low-income countries, and they make a substantial contribution to morbidity and mortality of individuals in these regions. Hence, owing to the increasing burden of hematological incidences and growing applications of apheresis as a treatment method for hematological disorders, the apheresis market for hematological disorders is expected to experience growth in the forecast period.
The recent years brought about a rise in new options of therapeutic apheresis, such as immunoadsorption, double filtration and cytapheresis used in the treatment of both primary and secondary autoimmune renal diseases. Those methods, more selective and safer than the classic TA, are potentially more efficient in the removal of pathogens, thus reducing the intoxication of the patient’s organism.
Asia-Pacific holds the Fastest Growth and is Expected to follow the Same Trend over the Forecast Period
The Asia-Pacific region is predicted to witness high growth, owing to the rising geriatric population and the increasing prevalence of several choric diseases. China is found to be one of the largest consumers and manufacturers in the global plasma-derived products market and serves a vast population. Great progress has been made in the Chinese plasma fractionation industry in the past 50 years. Moreover, increasing healthcare expenditure is another critical factor that is likely to enhance the growth of the market in the near future.
Competitive Landscape
The market studied is dominated by a few major players, and currently, the market is well established in many areas and has shown nascent success history. However, its full potential is yet to be determined in the developing regions. With increasing government initiatives, there is an awareness among people, which is further driving the growth of the market studied.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1. Introduction
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. Research Methodology
3. Executive Summary
4. Market Dynamics
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Global Disease Burden
4.2.2 Rise in Demand for Blood Components and Associated Safety
4.2.3 Technological Advancement in Development of New Apheresis Techniques
4.2.4 Rise in the Reimbursement Policies and Funding for Apheresis Procedures
4.3 Market Restraints
4.3.1 High Capital Investment and Costs Associated with Apheresis Procedures
4.3.2 Lack of Qualified Skilled Professionals
4.3.3 Risk of Blood Contamination
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. Market Segmentation
5.1 By Product
5.1.1 Devices
5.1.2 Disposables
5.1.2.1 Interventional/Surgical Simulators
5.2 By Apheresis Procedure
5.2.1 Leukapheresis
5.2.2 Plasmapheresis
5.2.3 Plateletpheresis
5.2.4 Erythrocytapheresis
5.2.5 Other Apheresis Procedures
5.3 By Technology
5.3.1 Centrifugation
5.3.2 Membrane Separation
5.4 By Application
5.4.1 Renal Disorders
5.4.2 Hematological Disorders
5.4.3 Neurological Disorders
5.4.4 Autoimmune Disorders
5.4.5 Other Applications
5.5 Geography
5.5.1 North America
5.5.1.1 United States
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 Germany
5.5.2.2 United Kingdom
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Rest of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 Japan
5.5.3.3 India
5.5.3.4 Australia
5.5.3.5 South Korea
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle East & Africa
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle East & Africa
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America
6. Competitive Landscape
6.1 Company Profiles
6.1.1 Asahi Kasei Corporation
6.1.2 B. Braun Melsungen AG
6.1.3 Cerus Corporation
6.1.4 Fresenius SE & Co. KGaA
6.1.5 Haemonetics Corporation
6.1.6 HemaCare Corporation
6.1.7 Kaneka Corporation
6.1.8 Kawasumi Laboratories Inc.
6.1.9 Terumo Corporation
6.1.10 Therakos Inc.
7. Market Opportunities and Future Trends
Market Segmentation
- By Product
Devices
Disposables
Interventional/Surgical Simulators
By Apheresis Procedure
Leukapheresis
Plasmapheresis
Plateletpheresis
Erythrocytapheresis
Other Apheresis Procedures
By Technology
Centrifugation
Membrane Separation
By Application
Renal Disorders
Hematological Disorders
Neurological Disorders
Autoimmune Disorders
Other Applications
Geography
North America
United States
Canada
Mexico - Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Defibrillator Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 110 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 110 pages
- Published: 07-06-2019
Market Overview
The growth of the defibrillator market can be attributed to factors such as technological advancements in the field of defibrillators and training and awareness programs for defibrillators. According to the American Heart Association’s research program, cardiovascular diseases are listed as the primary cause of deaths, and accounted for nearly 836,546 deaths in the United States. The deaths related to cardiovascular diseases are higher when compared to deaths related to all forms of cancer and chronic lower respiratory diseases combined. As per the American Heart Association, cardiovascular disease is the leading cause of death, globally, accounting for more than 17.9 million deaths per year in 2015, a number that is expected to grow to more than 23.6 million by 2030. Hence, the increase in prevalence of cardiovascular diseases is expected to drive the market growth.
Scope of the Report
Defibrillator is a life-saving device that helps deliver a therapeutic shock to a patient’s heart in life-threatening conditions, such as ventricular fibrillation, cardiac arrhythmia, and pulseless ventricular tachycardia. In the United States, approximately 300,000 out-of-hospital cardiac arrests occur each year. Supportive government policies in developed countries may help increase the availability and access of defibrillators, which will likely further boost the market growth over the forecast period.
Key Market Trends
Implantable Cardioverter Defibrillator(ICD) Spearheaded the Defibrillator Market
The implantable cardioverter defibrillator (ICD) segment accounted for the largest share in the global market. The ICDs are of three major types, namely transvenous ICDs, subcutaneous ICDs, and CRT with pacemaker and ICD function. The transvenous and subcutaneos ICDs are expected to exhibit the fastest growth rate over the forecast period, owing to the rising technological advancements, increasing R&D, and benefits associated with these ICDs. The overall ICD segment contributes for the largest market share, owing to the rising integration of multiple technological capabilities in a single device, such as defibrillators and pacemakers. In addition, the efficacy of these devices to manage arhythmias for a prolonged period is expected to drive the segment growth over the forecast period.
North America Dominated the Global Defibrillator Market
Cardiovascular diseases, listed as the underlying cause of death, account for nearly 836,546 deaths (about 1 of every 3 deaths) in the United States. Thus, the increasing prevalence of cardiovascular diseases in the region is expected to drive the growth of this market over the forecast period. In 2017, the Department of Health and Human Services (HHS), along with a number of public and private partners, launched the Million Hearts initiative that aims to prevent one million heart attacks and strokes. All the aforementioned factors are expected to boost the market growth.
Competitive Landscape
The major players operating in the defibrillators market are Boston Scientific Corporation, Koninklijke Philips NV., Medtronic, Nihon Kohden Corporation, and Abbott Laboratories. The key strategies adopted by the major market players are acquisitions and mergers, new product developments, geographical expansions, and enhanced marketing strategies.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1. Introduction
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. Research Methodology
3. Executive Summary
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Cardiovascular Diseases
4.2.2 Technological Advancements in the Field of Defibrillators
4.2.3 Training and Awareness Programs about Defibrillators
4.3 Market Restraints
4.3.1 High Costs of Defibrilators
4.3.2 Stringent Regulatory Framework
4.4 Industry Attractiveness Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. Market Segmentation
5.1 By Product
5.1.1 Implantable Cardioverter Defibrillator
5.1.1.1 Transvenous Implantable Cardioverter Defibrillator (T-ICDs)
5.1.1.2 Subcutaneous Implantable Cardioverter Defibrillator (S-ICDs)
5.1.1.3 CRT with Pacemaker and ICD Function (CRT-D)
5.1.2 External Defibrillator (ED)
5.1.2.1 Automated External Defibrillator (AEDs)
5.1.2.1.1 Semi-automated External Defibrillators
5.1.2.1.2 Fully-automated External Defibrillators
5.1.2.2 Manual External Defibrillator
5.1.2.3 Wearable Cardioverter Defibrillators (WCDs)
5.2 By End User
5.2.1 Hospitals
5.2.2 Emergency Care
5.2.3 Home Care
5.2.4 Other End Users
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 United Kingdom
5.3.2.2 Germany
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6. Competitive Landscape
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 Boston Scientific Corporation
6.1.3 Cardiac Science Corporation
6.1.4 Defibtech LLC
6.1.5 Koninklijke Philips NV
6.1.6 LivaNova PLC
6.1.7 Medtronic plc.
6.1.8 NIHON KOHDEN CORPORATION
6.1.9 Physio-Control Inc.
6.1.10 ZOLL Medical Corporation
7. Market Opportunities and Future Trends
Market Segmentation
- By Product
Implantable Cardioverter Defibrillator
Transvenous Implantable Cardioverter Defibrillator (T-ICDs)
Subcutaneous Implantable Cardioverter Defibrillator (S-ICDs)
CRT with Pacemaker and ICD Function (CRT-D)
External Defibrillator (ED)
Automated External Defibrillator (AEDs)
Semi-automated External Defibrillators
Fully-automated External Defibrillators
Manual External Defibrillator
Wearable Cardioverter Defibrillators (WCDs)
By End User
Hospitals
Emergency Care
Home Care
Other End Users
Geography
North America
United States
Canada
Mexico - Europe
United Kingdom
Germany
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Anti-obesity Drugs Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 118 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 118 pages
- Published: 07-06-2019
Market Overview
The anti-obesity drugs market is growing steadily with the gradual growth in the number of approvals from the US FDA and Europe EMA. North America, especially the United States, dominates this market, due to better healthcare services and high expenditure, followed by Europe. Till 2012, Xenical (orlistat) and generic phentermine were among the only approved drugs. However, the period between 2012 and 2016 saw high growth in the number of major pharmaceutical companies investing largely on clinical trials.
However, there are still very fewer drugs in the late stage of development. Owing to the less success rate and withdrawal among the centrally acting drugs, several of the major companies have considered the development of anti-obesity drugs as prohibitively risky and shifted the companies’ inclination toward broadening the scope of a diabetic portfolio into obesity. Since several companies have developed a strong relationship between Type 2 diabetes and obesity, it is often considered to be a low-risk strategy and minor investments in the R&D for potential anti-obesity drugs. Currently, the market is gradually growing its authority in the developing regions with the gradual approval of drugs, globally. However, it holds great potential with the aforementioned advantages, as several companies are targeting dual therapy mode for the treatment of obesity.
The Scope of the Report
An ideal anti-obesity drug would help in reducing sustained weight with minimal side effects. Mechanisms that control energy balance have considerable built-in redundancy, overlap with other physiological functions, and are subjected to social and psychological factors that restrict the effectiveness of pharmacological interventions. The anti-obesity drug market is segmented on the basis of the mechanism of action (peripherally acting and centrally acting anti-obesity drugs) and drug type (prescription and OTC drugs).
Key Market Trends
OTC Drugs Segment is Expected to Exhibit Fastest Growth Rate over the Forecast Period
In the present scenario, the weight problem is a major concern, globally. The rising intake of junk food/fast food is resulting in declining healthiness worldwide. As mentioned earlier, obesity is one of the most prevalent problems faced by people of this century. According to WHO, in 2016, more than 1.9 billion adults, ranging between 18 years and older, were overweight. Out of the aforementioned numbers, over 650 million were obese. With intentions to offer weight loss solutions, the companies have developed a number of weight loss products, of which a considerable proportion are OTC drugs.
In most countries, Orlistat is marketed as a prescription drug under the trade name Xenical, by Roche, and it is sold as an OTC drug under the trade name Alli, by GlaxoSmithKline, in the United Kingdom and the United States. Currently, the number of OTC drugs approved in the market is very less. However, the cost-effectiveness and ease of availability of OTC products are expected to propel the growth of the market.
North America Captured the Largest Market Share and is Expected to Retain its Dominance
North America dominated the global anti-obesity drugs market, with the United States accounting for the major contributor to the market. The primary factors driving the growth of the market studied are an increase in obese population and high healthcare spending. In the past few decades, several anti-obesity drugs are withdrawn from the market, due to reported and documented adverse effects. After years of interruption, the US Food and Drug Administration (FDA) has recently approved multiple new anti-obesity drugs. Majority of these medications are administered orally, and only one is administered subcutaneously. According to the data published by the Centers for Disease Control and Prevention (CDC), the prevalence of obesity was 39.8% and affected about 93.3 million US adults in 2015-2016, hence propelling the anti-obesity drugs market.
Competitive Landscape
The presence of major market players, such as GlaxoSmithKline, Novo Nordisk, Pfizer, F Hoffmann-La Roche, and Bayer AG, is, in turn, increasing the overall competitive rivalry of the market. Large organizations rely heavily on advertising expenses and branding strategies, collaborating with successful personality, initiative, or programs at the national levels, which promote their product, and thus are recognized earlier than other brands in the market. With the high prevalence rate of the disease, the intensity of competitive rivalry is moderate to high.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1. Introduction
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. Research Methodology
3. Executive Summary
4. Market Dynamics
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increase in Prevalence of Obesity
4.2.2 Sedentary Lifestyle
4.3 Market Restraints
4.3.1 Availability of Alternative Treatment Options
4.3.2 Side Effects of Drugs
4.3.3 High Drug Development Costs
4.4 Industry Attractiveness- Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. Market Segmentation
5.1 Mechanism of Action
5.1.1 Peripherally Acting Anti-obesity Drugs
5.1.2 Centrally Acting Anti-obesity Drugs
5.2 Drug Type
5.2.1 Prescription Drugs
5.2.2 OTC drugs
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 United Kingdom
5.3.2.2 Germany
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6. Competitive Landscape
6.1 Company Profiles
6.1.1 Arena Pharmaceuticals
6.1.2 GlaxoSmithKline
6.1.3 Nalpropion Pharmaceuticals Inc.
6.1.4 F Hoffmann-La Roche
6.1.5 Vivus
6.1.6 Bayer AG
6.1.7 Novo Nordisk
6.1.8 Pfizer
6.1.9 Eisai
7. Market Opportunities And Future Trends
Market Segmentation
- Mechanism of Action
Peripherally Acting Anti-obesity Drugs
Centrally Acting Anti-obesity Drugs
Drug Type
Prescription Drugs
OTC drugs
Geography
North America
United States
Canada
Mexico
Europe
United Kingdom
Germany
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific - Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
UAE In-Vitro Diagnostics Market – Growth, Trends & Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 85 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 85 pages
- Published: 07-06-2019
Market Overview
The growth of the UAE IVD market can be attributed to the high prevalence of chronic and infectious diseases. Chronic diseases are a growing global challenge, and according to WHO estimates, account for approximately 60% of all deaths, worldwide. In addition, WHO states that chronic diseases, such as cancer, cardiovascular diseases, diabetes, and chronic respiratory diseases are responsible for 12%, 40%, 5%, and 5% of mortality in the United Arab Emirates. The current market is also growing due to the use of advanced technologies in the IVD market. There has been a paradigm shift from traditional diagnostics to a new generation diagnostics, that works at the gene level. This was made possible by the inclusion of advanced technologies, such as genetic testing, molecular diagnostics, polymerase chain reaction (PCR), and next-generation sequencing (NGS).
Scope of the Report
In-vitro diagnostics involves medical devices and consumables that are utilized to perform in-vitro tests on various biological samples. They are used for the diagnosis of various medical conditions, such as chronic diseases.
Key Market Trends
Reagents Segment holds the Largest Market Share in the Product Type Segment
Reagents capture the largest market share and are expected to exhibit the fastest growth rate over the forecast period, owing to repeat purchase and increasing demand. The reagent segment of the market studied includes chemical, biological, or immunological components, solutions, and preparations intended by the manufacturer to be used during the in-vitro diagnostic process. Given the high cost of many diagnostic platforms, it is common for manufacturers to lease equipment instead of selling technology outright to end users. In these arrangements, the lease is tied to contracts to purchase associated reagents or assay kits for the equipment over the life of the contract.
Many diagnostic companies have in excess of 75% of sales from consumables, such as assays and reagents, and such agreements guarantee the generation of cyclic revenues associated with the sale of reagents and other consumables. Reagent usage for IVD kits often carry high costs,;hence, the availability of immunodiagnostic services in developing countries is often limited by the high cost of imported kits. Many developing countries have established local immunoassay reagent programs to manufacture low-cost, high-quality immunoassay reagents. Kits from these projects are now beginning to become available and are likely to fuel the market expansion.
Competitive Landscape
The major market players in the UAE in-vitro diagnostics market are bioMérieux, Qiagen, Abbott Laboratories, and Roche Diagnostics, and Siemens among others. The competition among manufacturers is increasing, with the increasing number of companies. Small manufacturers represent an unorganized market due to the lower prices of their products.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1. Introduction
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. Research Methodology
3. Executive Summary
4. Market Dynamics
4.1 Market Overview
4.2 Market Drivers
4.2.1 High Prevalence of Chronic Diseases
4.2.2 Increasing Use of Point-of-care (POC) Diagnostics
4.2.3 Technological Advancements
4.2.4 Increasing Awareness and Acceptance of Personalized Medicine and Companion Diagnostics
4.3 Market Restraints
4.3.1 Stringent Regulations
4.3.2 Cumbersome Reimbursement Procedures
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. Market Segmentation
5.1 By Technique
5.1.1 Immunochemistry
5.1.2 POC Diagnostics
5.1.3 Molecular Diagnostics
5.1.4 Hematology
5.1.5 Tissue Diagnostics
5.1.6 Microbiology
5.1.7 Self-blood Glucose Monitoring
5.1.8 Other Techniques
5.2 By Product
5.2.1 Instrument
5.2.2 Reagent
5.2.3 Data Management System
5.3 By Usablity
5.3.1 Disposable IVD Devices
5.3.2 Reusable IVD Devices
5.4 By Application
5.4.1 Infectious Disease
5.4.2 Diabetes
5.4.3 Cancer/Oncology
5.4.4 Cardiology
5.4.5 Autoimmune Disease
5.4.6 Nephrology
5.4.7 Drug Testing
5.4.8 HIV/AIDS
5.4.9 Other Applications
5.5 End User
5.5.1 Laboratory & Academia
5.5.2 Hospitals and POC Testing Centers
5.5.3 Other End Users
6. Competitive Landscape
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 Becton, Dickinson and Company
6.1.3 bioMérieux
6.1.4 Bio-Rad Laboratories, Inc.
6.1.5 Danaher Corporation
6.1.6 Qiagen
6.1.7 F. Hoffmann-La Roche Ltd
6.1.8 Siemens Healthcare GmBH
6.1.9 Sysmex Corporation
6.1.10 Thermo Fisher Scientific
7. Market Opportunities and Future Trends
Market Segmentation
- By Technique
Immunochemistry
POC Diagnostics
Molecular Diagnostics
Hematology
Tissue Diagnostics
Microbiology
Self-blood Glucose Monitoring
Other Techniques
By Product
Instrument
Reagent
Data Management System
By Usablity
Disposable IVD Devices
Reusable IVD Devices
By Application
Infectious Disease
Diabetes
Cancer/Oncology
Cardiology
Autoimmune Disease
Nephrology
Drug Testing
HIV/AIDS
Other Applications - End User
Laboratory & Academia
Hospitals and POC Testing Centers
Other End Users
Alpha Emitter Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 115 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 115 pages
- Published: 07-06-2019
Market Overview
The global alpha emitter market was valued at USD 506.5 million in 2018, and it is estimated to be valued at USD 3302.99 million by 2024 while witnessing a CAGR of 36.69% over the forecast period of 2019-2024. Certain factors that are driving the market growth include increased awareness about the potential benefits of targeted alpha therapy, and the growing number of patients with cardiac and cancer ailments.
Targeted anticancer or alpha therapy (TAT) is gaining popularity with the increasing prevalence of cancer and cardiovascular diseases. Consumers are now increasingly aware of the potential benefits of targeted therapies to cure such ailments.
Furthermore, radioimmunotherapy with short-ranged and high-efficiency α-particles is a striking and promising treatment approach. α-particles have an advantage in targeted therapy because of their exceptionally high cell-killing ability. However, regulatory requirements pose a hurdle to translational research and clinical investigations. For instance, in the United States, all pharmacologic agents, including diagnostic radiopharmaceuticals and radiotherapeutics, undergo regulatory oversight by the FDA. Similarly, radiopharmaceuticals face additional scrutiny and undergo unique regulatory and approval pathways, across the world.
Scope of the Report
In therapeutic radiopharmaceuticals, radionuclides with alpha emitters play a significant role in treating cancers. Properties of alpha emitters have led to exert profound differences between this field and other fields of nuclear medicine. Due to their short range and high LET (deposit energy in a unit length of their pathway), alpha particles have remarkably been considered into medical research.
Key Market Trends
Medical Application in Ovarian Cancer is Expected to Observe the Highest Growth Rate over the Forecast Period
The ovarian cancer segment in the alpha emitter market is expected to witness the highest CAGR of 35.63% during the forecast period.
The growth rate is attributed to an increasing number of new diagnosis cases. As per the estimates of the American Cancer Society, in 2018, around 22,240 women were expected to receive a new diagnosis of ovarian cancer, and about 14,070 women would die from ovarian cancer.
Ovarian cancer uses radioimmunotherapy as locally injected adjuvant therapy. Trials have evaluated the practice of complete abdominal or moving-strip external-beam radiotherapy (EBRT) or non-specific i.p. radiotherapy, with colloid preparations of Au-198 or P-32 as adjuvant therapies.
Moreover, the adoption of targeted alpha therapy with higher LET and shorter wavelengths has been promising in the treatment process. This trend is expected to gain traction in the near future. In addition, a recent Phase I clinical trial involving At-211-MX35 F (ab′) showed significant efficacy, as therapeutic doses reached their targets in patients with ovarian cancer.
North America Dominates the Market and is Expected to do Same in the Forecast Period
North America currently dominates the alpha emitter market, and it is expected to continue its stronghold for a few more years. This region is expected to increase its market share in the future, owing to the fact that the increase in cardiac and neurological chronic diseases is the major driving factor for the market growth in the region. For instance, 223RaCl2 (Xofigo) is the first alpha-emitting radioisotope to gain registration in the United States for palliative therapy of prostate cancer bone metastases through indirect physiological targeting.
Moreover, according to the National Cancer Institute, the number of new cases of melanoma was 21.8 per 100,000 men and women, per year. Similarly, the rising prevalence of cancer is making it imperative for the healthcare professionals across Canada to increase the radiotherapy utilization for cancer treatment. This is directly affecting the growth of the alpha emitter market in the country.
Competitive Landscape
The global alpha emitter market is less competitive and consists of very few major players. Companies, like IBA Radiopharma Solutions, Bayer AG, Alpha Tau Medical Ltd, Actinium Pharmaceutical Inc., Telix Pharmaceuticals Ltd, RadioMedix Inc., and Fusion Pharmaceuticals hold the substantial market share in the global alpha emitter market.
A number of developments have been taking place in the market over recent years.
For example, in November 2017, Actinium Pharmaceuticals launched the AWE Program, aka Actinium Warhead Enabling Program, to enable collaborations based on its Actinium-225 Technology Platform. Whereas, in November 2017, Alpha Tau Medical entered a collaboration with IRST Italy to treat its first cancer patients. This is significant progress toward international expansion. This is also expected to enable the availability of Alpha DaRT radiotherapy all across Europe, Asia, as well as the United States.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1. Introduction
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. Research Methodology
3. Executive Summary
4. Market Dynamics
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increased Awareness About the Potential Benefits of Targeted Alpha Therapy
4.2.2 Increasing Number of Patients with Cardiac and Cancer Ailments
4.3 Market Restraints
4.3.1 Short Half-life of Radiopharmaceuticals
4.3.2 Stringent Regulatory Framework and Reimbursement Issues
4.3.3 Need for High Capital Investment
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. Market Segmentation
5.1 Type of Radionuclide
5.1.1 Terbium (Tb-149)
5.1.2 Astatine (At-211)
5.1.3 Bismuth (Bi-212)
5.1.4 Actinium (Ac-225)
5.1.5 Radium (Ra-223)
5.1.6 Lead (Pb-212)
5.1.7 Bismuth (Bi -213)
5.2 Medical Application
5.2.1 Glioma
5.2.2 Melanoma
5.2.3 Pancreatic Cancer
5.2.4 Ovarian Cancer
5.2.5 Thyroid
5.2.6 Bone Metastasis
5.2.7 Lymphoma
5.2.8 Endocrine Tumors
5.2.9 Other Medical Applications
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6. Competitive Landscape
6.1 Company Profiles
6.1.1 Actinium Pharmaceutical Inc.
6.1.2 Alpha Tau Medical Ltd
6.1.3 Bayer AG
6.1.4 Fusion Pharmaceuticals
6.1.5 IBA Radiopharma Solutions
6.1.6 RadioMedix Inc.
6.1.7 Telix Pharmaceuticals Ltd
7. Market Opportunities and Future Trends
Market Segmentation
- Type of Radionuclide
Terbium (Tb-149)
Astatine (At-211)
Bismuth (Bi-212)
Actinium (Ac-225)
Radium (Ra-223)
Lead (Pb-212)
Bismuth (Bi -213)
Medical Application
Glioma
Melanoma
Pancreatic Cancer
Ovarian Cancer
Thyroid
Bone Metastasis
Lymphoma
Endocrine Tumors
Other Medical Applications
Geography
North America
United States
Canada
Mexico - Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America